fbpx
QQQ
+ 1.60
342.77
+ 0.46%
DIA
+ 0.84
337.94
+ 0.25%
SPY
+ 1.57
419.29
+ 0.37%
TLT
-0.18
143.47
-0.13%
GLD
-0.26
167.21
-0.16%

Roth Capital Initiates Celladon At Buy

by
March 5, 2015 9:23 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Analysts at Roth Capital initiated coverage on Celladon Corporation (NASDAQ: CLDN) with a Buy rating.

Celladon shares have gained 70.15% over the past 52 weeks, while the S&P 500 index has surged 11.80% in the same period.

Celladon’s shares rose 10.69% to $21.75 in pre-market trading.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

H.C. Wainwright Initiates Coverage On Celladon, Cites Impressive Trial Results For Heart Failure Therapy

Benzinga's Top Initiations

UPDATE: Stifel Initiates Coverage on Celladon as Novel Gene Therapy Could Revolutionize Heart Failure Treatment